सभी अध्ययन
भर्तीचरण I और चरण II (एकीकृत) - मनुष्यों को पहली बार प्रशासनहस्तक्षेपात्मक

An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

This study, called a Phase 1/2 trial, is looking at a new medicine called GEN3014 (also known as HexaBody®-CD38). It's for adults with certain blood cancers, specifically Multiple Myeloma, Diffuse Large B Cell Lymphoma, and Acute Myeloid Leukemia, that have either returned after treatment or haven't responded to other medicines. The main goals are to find out if GEN3014 is safe, what side effects it might cause, and if it helps to treat these cancers. Researchers will also compare it to an existing medicine, DARZALEX, in some cases. This is an early-stage study, meaning it's one of the first times this medicine is being given to people.

एक नजर में

स्थिति
भर्ती
चरण
चरण I और चरण II (एकीकृत) - मनुष्यों को पहली बार प्रशासन
प्रायोजक
Genmab A/S
नामांकन लक्ष्य
52
प्रारंभ
30 सितम्बर 2024

यह अध्ययन किस बारे में है?

This study is a clinical trial, which is a type of medical research involving people. Its main purpose is to test a new medicine called GEN3014. This medicine is designed to treat certain blood cancers, specifically Multiple Myeloma, Diffuse Large B Cell Lymphoma, and Acute Myeloid Leukemia. These are cancers that affect blood cells and bone marrow. The study is particularly for people whose cancer has either come back after past treatments (relapsed) or hasn't responded to other medicines (refractory).

This trial is made up of two parts, called Phase 1 and Phase 2. Phase 1 trials are usually the first time a new medicine is given to people. The main focus at this stage is to check if the medicine is safe and to find the right dose. Phase 2 trials then look more closely at how well the medicine works, while still monitoring safety. The researchers will be carefully watching for any side effects and how the participants' bodies react to the medicine.

During the study, some participants will receive GEN3014, while others might receive DARZALEX, which is another medicine used for these conditions. By comparing the new medicine to an existing one, doctors can learn more about its potential benefits and risks. The goal is to see if GEN3014 could be a new and effective treatment option for these difficult-to-treat blood cancers.

मुख्य निष्कर्ष

  • Tests a new medicine (GEN3014) for specific blood cancers.
  • For adults whose cancer has returned or didn't respond to previous treatment.
  • Aims to check safety and how well the new medicine works.
  • Compares GEN3014 to an existing treatment (DARZALEX) in some cases.
  • Involves regular clinic visits and close health monitoring.
  • भागीदारी स्वैच्छिक है, और आप किसी भी समय वापस ले सकते हैं।.

कौन पात्र हो सकता है?

To join this study, you must be at least 18 years old. Both men and women can take part. The study is specifically for people who have one of three types of blood cancer: Multiple Myeloma, Diffuse Large B Cell Lymphoma, or Acute Myeloid Leukemia.

It's important that your cancer has either come back after you've had treatment for it before, or that it hasn't responded to your previous treatments. The study is looking for people in these specific situations.

There might be other health requirements or previous treatment details that determine if you can join. A doctor involved in the study will review your full medical history to see if it’s a good fit for you.

क्या यह अध्ययन आपके लिए उपयुक्त हो सकता है?

यह देखने के लिए इन त्वरित प्रश्नों का उत्तर दें कि क्या आप पात्र हो सकते हैं। यह केवल एक मार्गदर्शिका है — अंतिम निर्णय शोध टीम द्वारा लिया जाता है।.

  1. क्या आप 18 वर्ष या उससे अधिक आयु के हैं?
  2. Do you have Multiple Myeloma, Diffuse Large B Cell Lymphoma, or Acute Myeloid Leukemia?
  3. Has your cancer come back after a previous treatment?
  4. Or has your cancer not responded to previous treatments?
  5. क्या आप नियमित क्लिनिक अपॉइंटमेंट्स में शामिल हो सकते हैं?
अपने परिणाम देखने के लिए हर प्रश्न का उत्तर दें।.

भागीदारी में क्या शामिल है?

If you decide to take part in this study, you will receive either the new medicine GEN3014 or a standard medicine named DARZALEX. You will come to the clinic regularly for check-ups. During these visits, doctors will closely monitor your health by taking blood samples, checking your vital signs (like blood pressure and heart rate), and performing heart checks using an electrocardiogram (ECG). They will also ask you about how you are feeling and any side effects you might be experiencing.

Some visits might involve longer stays for observation after you receive the medicine. The total length of your participation can vary depending on how you respond to the treatment and the phase of the study you are in, but it will involve ongoing follow-up visits to track your progress and long-term health. The doctors will explain the exact schedule and duration to you in detail.

संभावित जोखिम और लाभ

Participating in a clinical trial might offer potential benefits, such as receiving a new medicine that isn't widely available yet, which could help your condition if current treatments aren't working. You'll also receive close medical attention and monitoring. However, there are also potential risks. The new medicine, GEN3014, might cause side effects, some of which could be serious or unexpected, as it's still being tested. You will be told about all known risks before you make a decision. Remember, your participation is completely voluntary, and you have the right to withdraw from the study at any time, for any reason, without it affecting your future medical care.

स्थान (7)

कुछ साइट स्थान अनुमानित हैं। हम इसे सुधार रहे हैं — कृपया यात्रा करने से पहले परीक्षण टीम से सत्यापित करें।.
  • —
    असत्यापित
    हंगरी
  • —
    असत्यापित
    स्पेन
  • —
    असत्यापित
    चेकिया
  • —
    असत्यापित
    स्वीडन
  • —
    असत्यापित
    डेनमार्क
  • —
    असत्यापित
    ग्रीस
  • —
    असत्यापित
    पोलैंड

सामान्य प्रश्न

यह अध्ययन किस प्रकार के कैंसर के लिए है?

This study is for adults with Multiple Myeloma, Diffuse Large B Cell Lymphoma, or Acute Myeloid Leukemia that have come back or not responded to previous treatments.

What is GEN3014?

GEN3014 is a new medicine being tested in this study to see if it can treat these specific blood cancers.

क्या मुझे निश्चित रूप से नई दवा मिलेगी?

Some participants will receive GEN3014, while others might receive DARZALEX, an existing medicine, as part of the study design.

'रिलैप्स्ड या रिफ्रैक्टरी' का क्या मतलब है?

It means your cancer has either returned after you've had treatment, or it hasn't responded to the treatments you've received.

मैं अध्ययन में कितने समय तक रहूँगा?

The length of time you'd be in the study will depend on your response to treatment and the specific part of the study you're in. This will be explained in detail.

और अधिक जानने के लिए कैसे पता करें

किसी अध्ययन में भाग लेने का निर्णय लेने से पहले हमेशा अपने जीपी या विशेषज्ञ से बात करें।.

भाग लेने में रुचि रखते हैं?

अपनी रुचि दर्ज करें

अपने विवरण साझा करें और अनुसंधान टीम के लिए "An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (Hexa…यदि आप पात्र हो सकते हैं तो आपसे संपर्क करेंगे। भाग लेने के लिए सहमति देने से पहले हमेशा अपने जीपी से बात करें।.

चर्चा

समुदाय चर्चा

हमारे फोरम द्वारा संचालित community.patient.info. कृपया सम्मानजनक रहें — यह चिकित्सा सलाह नहीं है।.